Mirdametinib not checked

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · PD-0325901

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 1 trial completes
Trials
3 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
How it’s given
“Mirdametinib will be administered as a single, oral, 4 mg dose in the morning on Day 1 for each study participant enrolled in the study.”In the company’s words, NCT06997276 on ClinicalTrials.gov
Tested for
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1), Hepatic Impairment, Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
Main trialPhase 2
“This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.”In the company’s words, NCT03962543 on ClinicalTrials.gov
Other names
PD-0325901

Other drugs for Plexiform Neurofibroma

All 9 drugs for Plexiform Neurofibroma

Coming up2

Changes1

Last 90 days

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 20 Sep 2023 MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Phase 1Recruiting 27 Nov 2026 Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Phase 1Not yet recruiting 21 Oct 2032 A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Phase 1/2Terminated 15 Jan 2025 Mirdametinib + BGB-3245 in Advanced Solid Tumors
Phase 1Completed 27 Feb 2026 To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mirdametinib

Following is part of Solo: you see every change to Mirdametinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in